4th Feb 2014 16:43
LONDON (Alliance News) - Vectura Group PLC Tuesday said partner Sandoz has received marketing authorisation from Bulgarian authorities for its new inhaler for patients with respiratory problems.
The product, known as AirFluSal Forspiro, is an inhaler for patients with asthma and chronic obstructive pulmonary disease.
It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary and Romania.
"Bulgaria has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of [chronic obstructive pulmonary disease]. The product's safety, efficacy and equivalence have been proven in multiple clinical trials," the company said in a statement.
Vectura initially developed the product and created the design of the inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura.
Vectura shares Tuesday closed at 157.00 pence, down 1.00 pence, or 0.6%.
By Samuel Agini; [email protected]; @samuelagini
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L